Harmony falls as genetic disorder drug fails late-stage trial
View all comments(0)
Shares of drug developer Harmony Biosciences HRMY.O fall 7.6% to $29.7
Company says its experimental drug, ZYN002, did not meet the main goal of a late-stage trial testing it in patients with Fragile X syndrome
Fragile X syndrome is a genetic disorder and one of the most common causes of inherited intellectual disability
HRMY says the drug did not meet the main goal of improvement in social avoidance primarily due to a higher-than-expected placebo response rate
Including session's move, stock down 12.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.